Strategic partnerships TVM Capital Life Science pursues a two-pronged strategy that includes early-stage therapeutics via Project-Focused Company and later-stage medical technologies, backed by a global pharma relationship with Eli Lilly. This suggests sales opportunities around co-development, strategic advisory, and scalable commercialization collaborations with portfolio companies seeking Lilly-aligned milestones or exit potential.

Transatlantic reach With an experienced cross-border team and investments spanning North America and the EU, TVM engages internationally. Targeted outreach could focus on cross-border licensing, joint ventures, and region-specific co-investments to accelerate portfolio company approvals, manufacturing, or regulatory strategy.

Investment capacity Managing approximately $900 million and leading Series A financings for innovative life sciences ventures, TVM presents opportunities for late-stage funding rounds, bridge financings, and syndicated investments with other investors, as well as potential advisory roles for portfolio fundraising and liquidity events.

Portfolio inflection Recent activity includes Vektor Medical and myo, and a collaboration with Cellestia Biotech, indicating ongoing momentum in therapeutics and digital health-adjacent platforms. Sales opportunities exist in strategic partnerships, co-commercialization, and alignment on regulatory pathways to reach key inflection points.

Tech and operations fit TVM’s portfolio and operations leverage modern tech stacks and digital health capabilities, suggesting receptivity to enterprise-level partnerships in data analytics, AI-driven diagnostics, regulatory affairs platforms, and remote monitoring solutions that can accelerate time-to-market for portfolio assets.